Table 5.

Multivariable Adjusted¹ Risk of Incident Symptoms at Post-stopping² by Prevalence of Symptoms Prior to Stopping³: WHI CEE sub-sample (n=3496)⁴

Symptom Prevalence Prior to Stopping	CEE %5 (N)6	Placebo % (N)	RR (95% CI)7	P8	P-int9
Hot Flashes
Not present	9.3 (1640)	2.2 (1663)	3.64 (2.54, 5.20)	<0.001	<0.001
Present	35.3 (34)	30.6 (62)	0.85 (0.44, 1.64)
Night Sweats
Not Present	9.3 (1588)	3.4 (1610)	2.30 (1.69, 3.13)	<0.001	0.008
Present	46.4 (84)	36.8 (114)	1.18 (0.82, 1.71)
Breast Sensitivity
Not Present	1.8 (1589)	1.2 (1688)	1.66 (0.89, 3.09)	0.03	0.41
Present	18.1 (83)	17.8 (45)	1.06 (0.47, 2.39)
Vaginal Dryness
Not Present	3.2 (1546)	2.4 (1586)	1.36 (0.87, 2.11)	0.87	0.12
Present	32.2 (118)	30.9 (136)	0.85 (0.58, 1.25)
Joint Pain
Not Present	18.3 (1146)	15.4 (1231)	1.24 (1.02, 1.51)	<0.001	0.47
Present	64.6 (511)	55.1 (497)	1.14 (1.03, 1.27)
Mood Swings
Not Present	3.4 (1561)	2.8 (1624)	1.17 (0.77, 1.78)	0.54	0.80
Present	34.0 (103)	29.0 (100)	1.27 (0.79, 2.05)

¹Adjusted for age at prior to stopping, years since menopause, prior hormone use and presence of baseline vasomotor symptoms.

²Incidence of moderate or severe symptoms after stopping study pills.

³Prevalence of moderate or severe symptoms prior to stopping study pills.

⁴Women that were eligible (were not deceased, stopped or lost to follow-up and were still taking study pills) and completed all surveys.

⁵Proportion of N reporting symptoms post-stopping.

⁶Number of participants in CEE or placebo with or without symptom prior to stopping, denominator of (5).

⁷Multivariate adjusted relative risk (95% confidence interval) of symptoms at post-stopping of CEE compared to placebo.

⁸Test of main effect.

⁹Test of interaction.